Structure of Pirarubicin
CAS No.: 72496-41-4
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Pirarubicin is an analogue of the anthracycline anti-neoplastic doxorubicin, which is an inhibitor of Topo II.
Synonyms: THP; NSC-333054
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 72496-41-4 |
Formula : | C32H37NO12 |
M.W : | 627.64 |
SMILES Code : | O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O |
Synonyms : |
THP; NSC-333054
|
MDL No. : | MFCD00869742 |
GHS Pictogram: |
![]() |
Signal Word: | Danger |
Hazard Statements: | H340-H350-H360 |
Precautionary Statements: | P201-P202-P280-P308+P313-P8624-P405-P501 |
Target |
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
H9C2 cardiomyocytes | 5 μM | 22 h | Establish THP-induced cell injury model, THP significantly decreased cell activity | PMC8554014 |
MDA-MB-468 | 3 μM | 24 h | To study the effect of THP on circZCCHC2 expression in MDA-MB-468 cells, the results showed that THP significantly downregulated circZCCHC2 expression. | PMC10867422 |
MDA-MB-231 | 5 μM | 24 h | To study the effect of THP on circZCCHC2 expression in MDA-MB-231 cells, the results showed that THP significantly downregulated circZCCHC2 expression. | PMC10867422 |
MDA-MB-231 cells | 20 μg/mL | 2 h | To evaluate the cellular uptake and drug release of P60-ICG-THP triggered by acidic pH, the results showed that THP could immediately cross the cell membrane and enter the nucleus at pH 6.5, while ICG was mainly located in the cytoplasm. | PMC7667678 |
HCM cells | 5 μM | 24 h | To evaluate the effect of Pirarubicin on the survival rate of HCM cells, the results showed that 5 μM Pirarubicin treatment for 24 h significantly reduced cell viability. | PMC10982373 |
H9c2 cells | 5 μM | 24 h | To evaluate the effect of Pirarubicin on the survival rate of H9c2 cells, the results showed that 5 μM Pirarubicin treatment for 24 h significantly reduced cell viability. | PMC10982373 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
BALB/c nude mice | Xenograft tumor model | Tail vein injection | 5 mg/kg | Once a week for four weeks | To study the effect of circZCCHC2 on THP sensitivity in vivo, the results showed that circZCCHC2 overexpression partially rescued the tumor inhibitory effect of THP. | PMC10867422 |
Nude mice | MDA-MB-231 tumor model | Caudal vein injection | 20 mg/kg | Once daily for 21 days | To evaluate the antitumor effect of P60-ICG-THP in vivo, the results showed that P60-ICG-THP significantly inhibited tumor growth through the combination of chemotherapy, photothermal therapy, and starvation therapy. | PMC7667678 |
Wistar rats | Pirarubicin-induced cardiotoxicity model | Caudal vein injection | 3 mg/kg | Once a week for 6 weeks | To evaluate the effect of Pirarubicin on cardiotoxicity in rats, the results showed that Pirarubicin significantly reduced cardiac function and increased serum levels of myocardial enzymes. | PMC10982373 |
SD rats | THP-induced cardiotoxicity model | Caudal vein injection | 3 mg/kg | Once a week for 8 weeks | To study THP-induced cardiotoxicity and observe the protective effect of SchB. THP caused decreased and food intake, abnormal ECG and echocardiogram, myocardial tissue damage, and increased cardiomyocyte apoptosis, which were effectively alleviated by SchB | PMC8554014 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03277716 | Hepatocellular Carcinoma Non-r... More >>esectable Transarterial Chemoembolization Microwave Ablation Less << | Not Applicable | Recruiting | December 30, 2021 | China, Beijing ... More >> Cancer Institute &Hospital, Chinese Academy of Medical Sciences Not yet recruiting Beijing, Beijing, China, 100021 Contact: Xiao Li, M.D China, Fujian The First Affiliated Hospital of Fujian Medical University Recruiting Fuzhou, Fujian, China, 350005 Contact: Zhenyu Lin, M.D. The tumor hospital of Fujian Province Not yet recruiting Fuzhou, Fujian, China, 350014 Contact: Hailan Lin, M.D China, Guangdong the First Affiliated Hospital of SunYat-senUniversity Not yet recruiting Guangzhou, Guangdong, China, 510080 Contact: Jiaping Li, M.D Shenzhen People's Hospital Recruiting Shenzhen, Guangdong, China, 518020 Contact: Yanfang Zhang, M.D. Peking University Hospital of Shenzhen Recruiting Shenzhen, Guangdong, China, 518036 Contact: Junhui Chen, M.D. China, Shandong The Second Affiliated Hospital of Shandong University Recruiting Jinan, Shandong, China, 250000 Contact: Yuliang Li, M.D Shandong Province Hospital Recruiting Jinan, Shandong, China, 250014 Contact: Xin Ye, M.D the Affiliated Hospital of Medical College Qingdao University Recruiting Qingdao, Shandong, China, 26555 Contact: Zixiang Li, M.D China, Zhejiang The First Affiliated Hospital of Zhejiang University Not yet recruiting Hangzhou, Zhejiang, China, 310003 Contact: Junhui Sun, M.D. Less << |
NCT00131053 | Lymphoblastic Leukemia, Acute | Phase 2 | Unknown | September 2011 | Japan ... More >> Department of Hematology, Nagoya University Graduate School of Medicine Recruiting Nagoya, Japan, 466-8550 Contact: Fumihiko Hayakawa, MD bun-hy@med.nagoya-u.ac.jp Principal Investigator: Fumihiko Hayakawa, MD Less << |
NCT02760953 | Urinary Bladder Neoplasms | Not Applicable | Not yet recruiting | December 31, 2018 | - |
NCT02435953 | Hepatocellular Carcinoma ... More >> Chemoembolization, Therapeutic Ablation Techniques, RFA Less << | Phase 4 | Recruiting | - | China, Guangdong ... More >> Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center, Recruiting Guangzhou, Guangdong, China, 500060 Contact: Ming Zhao, doctor +86 020 87343272 zhaoming@sysucc.org.cn Contact: Tao Pan, doctor +86 020 87343271 pantao0909@hotmail.com Less << |
NCT03503864 | Neuroblastoma | Phase 2 | Recruiting | December 30, 2029 | China, Guangdong ... More >> Sun Yat-sen Memorial Hospital, Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510120 Contact: Yang Li, Professor +8602081332456 drliyang@126.com Less << |
NCT01430013 | T Cell Lymphoma | Phase 2 | Unknown | December 2015 | China, Tianjin ... More >> Tianjin Medical University Cancer Institute and Hospital Tianjin, Tianjin, China, 300060 Less << |
NCT02956772 | Primary Hepatocellular Carcino... More >>ma Less << | Phase 2 | Not yet recruiting | November 2020 | China, Guizhou ... More >> Guizhou Cancer Hospital Not yet recruiting Guiyang, Guizhou, China Contact: Shi Zhou, Dr. 258600801@qq.com Guizhou Province Tumor Hospital Not yet recruiting Guiyang, Guizhou, China Contact: Junxiang Li, Dr. 258600801@qq.com China, Hunan Hunan Provincial People's Hospital Not yet recruiting Changsha, Hunan, China, 410001 Contact: Hua Xiang, Dr. +86-13667367061 Contact: Lin Long, Dr. +86-13507476175 doclongll@163.com Hunan Cancer Hospital Not yet recruiting Changsha, Hunan, China Contact: Guowen LI, Dr. liguowen@hnszlyy.com Xiangya Hospital Central South University Not yet recruiting Changsha, Hunan, China Contact: Chunhui Zhou, Dr. zhouchunhui2016@163.com The First Affiliated Hospital of University of South China Not yet recruiting Hengyang, Hunan, China Contact: Youhua Wu, Dr. 330270372@qq.com China, Jiangsu Jiangsu Province Hospital Not yet recruiting Nanjing, Jiangsu, China Contact: Zhen-Qiang Yang, Dr. ntdoctoryang@hotmail.com China, Xinjiang Xinjiang Medical University Cancer Hospital Not yet recruiting Urumqi, Xinjiang, China Contact: Shufa Yang, Dr. yangshufa2013@sina.com China, Yunnan The Tumor Hospital of Yunnan Province Not yet recruiting Kunming, Yunnan, China Contact: Ming Huang, Dr. huangming4328@sina.com Less << |
NCT02396043 | Lymphoma, Lymphoblastic | Phase 2 | Recruiting | March 2020 | China, Guangdong ... More >> Sun Yat-sen University Cancer Center Recruiting GuangZhou, Guangdong, China, 510060 Contact: Zhongjun Xia, MD. 0086-02087342438 zhongjunxia_64@sina.com Less << |
NCT03121833 | Soft Tissue Sarcoma, Adult, St... More >>age IIB Less << | Phase 2 | Recruiting | May 1, 2019 | China, Tianjin ... More >> Tianjin Medical University Cancer Hospital & Institute Recruiting Tianjin, Tianjin, China, 300060 Contact: Jilong Yang, M.D., Ph.D. +8618622221626 yangjilong@tjmuch.com Less << |
NCT02301091 | Hepatocellular Carcinoma | Phase 3 | Recruiting | October 2019 | China, Guangdong ... More >> Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center, Recruiting Guangzhou, Guangdong, China, 500060 Contact: Ming Zhao, doctor +86 020 87343272 zhaoming@sysucc.org.cn Less << |
NCT02838225 | Breast Cancer | Phase 2 | Completed | - | - |
NCT02525952 | Hepatocellular Carcinoma | Not Applicable | Unknown | December 2017 | China, Shanghai ... More >> Eastern hepatobilliary surgery hospital Recruiting Shanghai, Shanghai, China, 200438 Contact: Yong Xia, Doctor 86-021-81875495 Eastern hepatobilliary surgery hospital Recruiting Shanghai, Shanghai, China, 200438 Contact: Shen Feng, MD 0086-021-25070805 shenfengdfgd@yahoo.com.cn Contact: Wu Dong, MD 0086-021-25070765 wuyuz@yahoo.com.cn Principal Investigator: Shen Feng, MD Less << |
NCT02724358 | Hepatocellular Carcinoma ... More >> TACE Notch1 Rg3 Less << | Not Applicable | Completed | - | China, Shanghai ... More >> Eastern hepatobilliary surgery hospital Shanghai, Shanghai, China, 200438 Less << |
NCT02953184 | Antineoplastic Combined Chemot... More >>herapy Protocols Less << | Phase 2 | Recruiting | November 2020 | China, Jilin ... More >> First Hospital of Jilin University Recruiting Changchun, Jilin, China, 130021 Contact: Aiping Shi, Doctor 0086-13364308696 13364308696@163.com Contact: Zhimin Fan, Doctor 0086-13756661286 fanzhimn@163.com Sub-Investigator: Di Wu, Doctor Sub-Investigator: Hongyao Jia, Master Sub-Investigator: Xin Guan, Master Principal Investigator: Zhimin Fan, Doctor Principal Investigator: Haibo Wang, Doctor Sub-Investigator: Gang Nie, Doctor Less << |
NCT02585479 | Hepatocellular Carcinoma | Phase 2 Phase 3 | Unknown | October 2017 | - |
NCT02584556 | Hepatocellular Carcinoma | Phase 2 Phase 3 | Unknown | October 2017 | - |
NCT02755311 | Hepatocellular Carcinoma | Phase 3 | Unknown | June 2016 | China, Guangdong ... More >> The First Affiliated Hospital of Sun Yat-sen University Recruiting Guangzhou, Guangdong, China, 510080 Contact: Zhenwei Peng, MD pengzhenwei2005@163.com Less << |
NCT02547350 | Upper Tract Urothelial Carcino... More >>ma Bladder Recurrence Less << | Phase 2 | Not yet recruiting | - | - |
NCT02740426 | Upper Tract Urothelial Carcino... More >>ma|Bladder Recurrence Less << | PHASE2 | UNKNOWN | 2025-05-22 | Peking University First Hospit... More >>al, Beijing, Beijing, 100034, China Less << |
NCT02613026 | Breast Neoplasms | Phase 3 | Completed | - | China, Hebei ... More >> The fourth hospital of Hebei Medical University Shijiazhuang, Hebei, China, 050010 China, Heilongjiang Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China, 150081 China, Hunan Hunan Provincial People's Hospital Changsha, Hunan, China, 410005 Xiangya Hospital, Central South University Changsha, Hunan, China, 410008 China, Jiangsu Jiangsu Cancer Hospital Nanjing, Jiangsu, China, 210000 Less << |
NCT02923557 | Bladder Recurrence|Upper Tract... More >> Urothelial Carcinoma|Nephroureterectomy Less << | PHASE2 | UNKNOWN | - | Peking University Frist Hospit... More >>al, Beijing, Beijing, 10034, China Less << |
NCT01249690 | Multiple Myeloma | Phase 4 | Unknown | June 2014 | China, Shang Hai ... More >> Shanghai Changzheng Hospital Recruiting Shang Hai, Shang Hai, China, 200003 Contact: Hou houjian_czyy@sina.cn Principal Investigator: Jian Hou Less << |
NCT01746992 | ALK-negative Anaplastic Large ... More >>Cell Lymphoma Peripherial T Cell Lymphoma,Not Otherwise Specified Angioimmunoblastic T Cell Lymphoma Enteropathy Associated T Cell Lymphoma Hepatosplenic T Cell Lymphoma Subcutaneous Panniculitis Like T Cell Lymphoma Less << | Phase 4 | Active, not recruiting | December 2018 | China, Shanghai ... More >> Ruijin hospital Shanghai, Shanghai, China, 200025 Less << |
NCT02903524 | Breast Cancer | Phase 4 | Unknown | December 2018 | China, Hebei ... More >> Fourth Hospital of Hebei Medical University Recruiting Shi Jiazhuang, Hebei, China, 050019 Contact: Geng Cuizhi, archiater 0311-66696310 gengcuizhi@hotmail.com Less << |
NCT03030157 | Intravesical Instillation | Phase 2 | Recruiting | - | China, Shanghai ... More >> Renji Hospital Recruiting Shanghai, Shanghai, China, 200127 Contact: jiwei huang, M.D 8613651682825 jiweihuang@outlook.com Contact: jin zhang 86-21-68383776 zhangjin@renji.com Less << |
NCT03342300 | Progression-free Survival ... More >> Overall Survival Toxicity Less << | Phase 2 Phase 3 | Recruiting | December 30, 2019 | China ... More >> Peking University People's Hospital Recruiting Beijing, China, 100044 Contact: Tingting Ren, Ph.D. +86-13810095026 tumorcenter@163.com Principal Investigator: Wei Guo, M.D. and Ph.D. Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.59mL 0.32mL 0.16mL |
7.97mL 1.59mL 0.80mL |
15.93mL 3.19mL 1.59mL |
Tags: Pirarubicin | THP | Topoisomerase | Autophagy | Bacterial | Antibiotic | anthracycline chemotherapy | DNA intercalation | topoisomerase II inhibitor | ROS generation | 72496-41-4
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL